GlassScriptPhysician profile
Claudia J Vera
NPI 1811966534
$4,215.02
in general payments reported to CMS, 2019-2025
32 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $1,229 · 2021: $409 · 2022: $117 · 2023: $208 · 2024: $518 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $769.22 | 2019-2020 | |
| Allergan, INC. | $732.90 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $324.01 | 2019-2024 | Airsupra, Farxiga |
| Abbvie INC. | $298.74 | 2021-2025 | |
| Amgen INC. | $283.58 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.13 | 2019-2021 | |
| Astellas Pharma US INC | $239.35 | 2019-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $190.91 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Abbott Laboratories | $128.49 | 2021-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $101.10 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $97.94 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $95.13 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.26 | 2019-2024 | Gattex |
| Novo Nordisk INC | $81.60 | 2021-2024 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $69.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $48.89 | 2024-2025 | |
| Glaxosmithkline, LLC. | $47.25 | 2023-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $43.21 | 2019-2025 | Jardiance, Mounjaro |
| Phathom Pharmaceuticals, INC. | $38.81 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $38.55 | 2020-2021 | |
| Dexcom, INC. | $24.70 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $24.06 | 2025 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $23.71 | 2019 | |
| Inspire Medical Systems, INC. | $23.35 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $22.22 | 2024 | Rexulti |
| Seqirus USA INC | $18.43 | 2022 | |
| Exeltis, USA INC. | $16.69 | 2025 | Slynd |
| E.R. Squibb & Sons, L.L.C. | $16.60 | 2024 | Eliquis |
| Merck Sharp & Dohme LLC | $16.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.36 | 2024 | Xifaxan |
| Corcept Therapeutics | $16.09 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Vera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.